HK1076248A1 - Use of rimexolone in the treatment of dry eye - Google Patents

Use of rimexolone in the treatment of dry eye

Info

Publication number
HK1076248A1
HK1076248A1 HK05108569.9A HK05108569A HK1076248A1 HK 1076248 A1 HK1076248 A1 HK 1076248A1 HK 05108569 A HK05108569 A HK 05108569A HK 1076248 A1 HK1076248 A1 HK 1076248A1
Authority
HK
Hong Kong
Prior art keywords
rimexolone
treatment
dry eye
eye
dry
Prior art date
Application number
HK05108569.9A
Other languages
English (en)
Inventor
John M Yanni
Daniel A Gamache
Steven T Miller
Ernesto J Castillo
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of HK1076248A1 publication Critical patent/HK1076248A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK05108569.9A 2002-12-24 2005-09-28 Use of rimexolone in the treatment of dry eye HK1076248A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43625502P 2002-12-24 2002-12-24
PCT/US2003/040374 WO2004058273A1 (en) 2002-12-24 2003-12-18 Use of rimexolone in the treatment of dry eye

Publications (1)

Publication Number Publication Date
HK1076248A1 true HK1076248A1 (en) 2006-01-13

Family

ID=32682365

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108569.9A HK1076248A1 (en) 2002-12-24 2005-09-28 Use of rimexolone in the treatment of dry eye

Country Status (24)

Country Link
US (3) US20040132704A1 (pt)
EP (1) EP1575597B1 (pt)
JP (1) JP2006513213A (pt)
KR (2) KR20090018222A (pt)
CN (1) CN100388919C (pt)
AR (1) AR042790A1 (pt)
AT (1) ATE419856T1 (pt)
AU (1) AU2003299696B2 (pt)
BR (1) BR0317774A (pt)
CA (1) CA2507375C (pt)
CY (1) CY1108862T1 (pt)
DE (1) DE60325770D1 (pt)
DK (1) DK1575597T3 (pt)
ES (1) ES2316867T3 (pt)
HK (1) HK1076248A1 (pt)
MX (1) MXPA05006985A (pt)
PL (1) PL378877A1 (pt)
PT (1) PT1575597E (pt)
RU (1) RU2330668C2 (pt)
SI (1) SI1575597T1 (pt)
TW (1) TWI335819B (pt)
UY (1) UY28126A1 (pt)
WO (1) WO2004058273A1 (pt)
ZA (1) ZA200503975B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7779039B2 (en) 2004-04-02 2010-08-17 Salesforce.Com, Inc. Custom entities and fields in a multi-tenant database system
US8653055B2 (en) 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
JP5395434B2 (ja) 2005-09-09 2014-01-22 セールスフォース ドット コム インコーポレイティッド マルチテナントデータベース環境において、オンデマンドアプリケーションをエクスポートし、公表し、ブラウズし、インストールするためのシステムおよび方法
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8138156B2 (en) * 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
US8629099B2 (en) * 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
LT2432472T (lt) * 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
NO2437762T3 (pt) * 2009-06-05 2018-01-06
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
RU2559580C1 (ru) * 2014-03-18 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Препарат для лечения синдрома "сухого глаза"
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN106581035A (zh) * 2016-12-06 2017-04-26 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合物
CN106420797A (zh) * 2016-12-06 2017-02-22 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合及其制备方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
KR102269835B1 (ko) 2019-10-08 2021-06-29 한국전력공사 펜형 케이블 식별장치 및 케이블 식별 시스템
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20240166971A1 (en) * 2022-10-26 2024-05-23 Bausch + Lomb Ireland Limited Contact lens treating solution

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203620A (ja) * 1985-10-30 1988-08-23 アルコン　ラボラトリ−ズ　インコ−ポレイテツド 眼科用の抗炎症性組成物
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
JPH06153607A (ja) * 1992-11-30 1994-06-03 Kinsaku Kida 農耕用作業車と農耕作業部との連結装置
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
PL337458A1 (en) * 1997-06-04 2000-08-14 Akzo Nobel Nv Application of anti-inflammatory steroids in treating chronic intestinal inflammatory diseases
CN1158994C (zh) * 1999-09-24 2004-07-28 爱尔康公司 含环丙沙星和地塞米松的局部悬浮制剂

Also Published As

Publication number Publication date
US20060058277A1 (en) 2006-03-16
SI1575597T1 (sl) 2009-04-30
JP2006513213A (ja) 2006-04-20
ATE419856T1 (de) 2009-01-15
ZA200503975B (en) 2006-12-27
AU2003299696A1 (en) 2004-07-22
EP1575597B1 (en) 2009-01-07
CN100388919C (zh) 2008-05-21
KR100889170B1 (ko) 2009-03-16
KR20090018222A (ko) 2009-02-19
CA2507375C (en) 2009-11-24
BR0317774A (pt) 2005-11-22
PL378877A1 (pl) 2006-05-29
DK1575597T3 (da) 2009-03-16
WO2004058273A1 (en) 2004-07-15
MXPA05006985A (es) 2005-08-16
CA2507375A1 (en) 2004-07-15
EP1575597A1 (en) 2005-09-21
AU2003299696B2 (en) 2009-08-13
RU2005123388A (ru) 2006-01-20
DE60325770D1 (de) 2009-02-26
AR042790A1 (es) 2005-07-06
TW200418492A (en) 2004-10-01
CN1732008A (zh) 2006-02-08
CY1108862T1 (el) 2014-07-02
PT1575597E (pt) 2009-02-02
ES2316867T3 (es) 2009-04-16
UY28126A1 (es) 2004-06-30
US20040132704A1 (en) 2004-07-08
US20080096852A1 (en) 2008-04-24
KR20050086937A (ko) 2005-08-30
TWI335819B (en) 2011-01-11
RU2330668C2 (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
HK1076248A1 (en) Use of rimexolone in the treatment of dry eye
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
IL172316A0 (en) Novel compounds and their use in therapy
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1068778A1 (en) Insert for the treatment of dry eye
EP1543034A4 (en) TREATMENT AND PROPHYLAXIS WITH 4-1BB BINDING AGENTS
EP1581243A4 (en) ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES
GB0108671D0 (en) Skin treatment
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
AU2003227944A1 (en) Ddah modulators in the treatment of pain
EP1558238A4 (en) BETA-HYDROXYPHENYL ALDYLAMINE AND ITS USE FOR THE TREATMENT OF GLAUCOMA
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
SG110107A1 (en) Compound and use in treatment
IL164951A0 (en) The treatment of pain with lfendropil
EP1683765A4 (en) WATER TREATMENT UNIT AND APPARATUS PROVIDED WITH THIS UNIT
GB0106316D0 (en) Apparatus for use in the treatment of hair
GB2392839A8 (en) Use of Mycobacterium w in the treatment of tubercolosis
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
GB2386839B (en) Apparatus for use in the treatment of choanal atresia
GB0312340D0 (en) Improved game and aricle for use with the game
IL174968A0 (en) The use of ifenprodil in the treatment of pain

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121218